Caisse de depot et placement du Quebec Takes $25.81 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Caisse de depot et placement du Quebec bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 85,748 shares of the biopharmaceutical company’s stock, valued at approximately $25,813,000. Caisse de depot et placement du Quebec owned about 0.06% of Alnylam Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares during the period. Golden State Wealth Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.4% during the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 38 shares during the period. Atlantic Union Bankshares Corp grew its stake in Alnylam Pharmaceuticals by 20.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 40 shares during the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC raised its holdings in Alnylam Pharmaceuticals by 3.3% in the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 40 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. BMO Capital Markets initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, August 19th. They issued an “outperform” rating and a $318.00 price objective on the stock. Bank of America cut their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Wells Fargo & Company lowered their target price on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Alnylam Pharmaceuticals Stock Up 0.2%

Shares of ALNY stock opened at $237.10 on Friday. The stock has a market cap of $31.73 billion, a P/E ratio of 44.07 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The stock has a fifty day moving average price of $262.62 and a 200 day moving average price of $293.73. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the firm posted ($0.51) EPS. The business’s revenue for the quarter was up 66.9% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.